La Jolla Buy Hold or Sell Recommendation

LJPC -- USA Stock  

Earnings Report: March 2, 2020  

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding La Jolla Pharmaceutical Company is 'Hold'. Macroaxis provides La Jolla buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding La Jolla positions. The advice algorithm takes into account all of La Jolla Pharmaceutical available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from La Jolla buy-and-hold prospective. Please see also La Jolla Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Execute Advice
Sell La JollaBuy La Jolla

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

For the selected time horizon La Jolla Pharmaceutical Company has a risk adjusted performance of (0.13), jensen alpha of (0.61), total risk alpha of (0.84), sortino ratio of 0.0 and treynor ratio of (0.71)
We provide buy or sell recommendation to complement the latest expert consensus on La Jolla Pharmaceutical Company. Our dynamic recommendation engine harnesses multi - dimensional algorithm to analyze the entity potential to grow using all technical and fundamental data available at this time. To make sure La Jolla Pharmaceutical is not overpriced, please verify all La Jolla Pharmaceutical Company fundamentals including its Gross Profit, Book Value Per Share and the relationship between Price to Earning and Cash per Share . Given that La Jolla Pharmaceutical has Number of Shares Shorted of 3.78 M, we recommend you check La Jolla market performance and probability of bankruptcy to make sure the company can sustain itself in the coming quarters given your latest risk tolerance and investing horizon.

La Jolla Trading Alerts and Improvement Suggestions

La Jolla generates negative expected return over the last 30 days
La Jolla has high historical volatility and very poor performance
La Jolla has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 17.75 M. Net Loss for the year was (158.26 M) with loss before overhead, payroll, taxes, and interest of (106.49 M).
LA JOLLA PHARMA currently holds about 123.45 M in cash with (118.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.55.
Over 105.0% of the company shares are owned by institutional investors
Latest headline from La Jolla Pharmaceutical Company Plunges 5.83 percent on November 13 -

La Jolla current analysts recommendations

Target Median Price21.00
Target Mean Price20.17
Recommendation Mean2.20
Target High Price27.00
Number Of Analyst Opinions6
Target Low Price7.00

La Jolla Returns Distribution Density

Mean Return0.54Value At Risk5.83
Potential Upside4.28Standard Deviation3.15
 Return Density 

La Jolla Greeks

Alpha over DOW
Beta against DOW=0.77
Overall volatility
Information ratio =0.2

La Jolla Volatility Alert

La Jolla Pharmaceutical Company exhibits very low volatility with skewness of -0.23 and kurtosis of 0.39. However, we advise investors to further study La Jolla Pharmaceutical Company technical indicators to make sure all market info is available and is reliable.
 Better Than Average     
 Worse Than Average Compare La Jolla to competition

La Jolla Fundamental Vs Peers

FundamentalsLa JollaPeer Average
Return On Equity(3.07) (0.31) 
Return On Asset(0.41) (0.14) 
Profit Margin(41.22) (1.27) 
Operating Margin(816.09) (5.51) 
Current Valuation238.81 M16.62 B
Shares Outstanding27.13 M571.82 M
Shares Owned by Insiders6.08 10.09 
Shares Owned by Institutions104.64 39.21 
Number of Shares Shorted3.78 M4.71 M
Price to Earning(6.45) 28.72 
Price to Book30.11 9.51 
Price to Sales10.37 11.42 
Revenue17.75 M9.43 B
Gross Profit(106.49 M)27.38 B
EBITDA(140.29 M)3.9 B
Net Income(158.26 M)570.98 M
Cash and Equivalents123.45 M2.7 B
Cash per Share4.55 5.01 
Total Debt154.89 M5.32 B
Debt to Equity7.16 48.70 
Current Ratio6.02 2.16 
Book Value Per Share(113.55) 1.93 K
Cash Flow from Operations(118.15 M)971.22 M
Short Ratio14.27 4.00 
Earnings Per Share(5.92) 3.12 
Price to Earnings To Growth(0.12) 4.89 
Number of Employees16918.84 K
Market Capitalization184.05 M19.03 B
Total Asset89.52 M29.47 B
Retained Earnings(438.79 M)9.33 B
Working Capital79.5 M1.48 B
Current Asset86.74 M9.34 B
   Purchase by Kevin Tang of 6500 shares of La Jolla [view details]